Tami Daugherty

Alcoholic and non alcoholic steatohepatitis are major causes of end stage liver disease. My goal as a clinician-scientist is to develop new treatment approaches that improve patient outcomes. My research lab is studying the pathomechanism of liver fibrosis and we are focusing on discovering novel therapies and translating them to clinical care.

Dr. Eldika received his medical education at the American University of Beirut. He completed his General Gastroenterology Fellowship at the State University of New York in Buffalo and Advanced Endoscopy Fellowship at the University of Virginia. At Ohio State University, he served as the Director of Interventional Endoscopy and Endoscopic Quality. His time at Ohio State University contributed to the growth and maturity of his experience and skills in interventional endoscopy. During his tenure there, he played a major role in building the program of interventional endoscopy in general, as well as interventional endoscopy for the pediatric age group, and the endoscopic quality program.

Dr. Kwo is currently Professor of Medicine and Director of Hepatology at the Stanford University where he joined the faculty in November 2016. Prior to joining the faculty at Stanford, he was at Indiana University for 21 years where he served as the Medical Director of Liver Transplantation. He has distinguished himself in the field of Hepatitis C therapeutics and has been the principal investigator on multiple international trials. He recently authored the ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.